# Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

> **NCT01465230** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 2 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Maintenance lenalidomide

## Key facts

- **NCT ID:** NCT01465230
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** This study was unsuccessful in enrolling the target number of subjects during the funding period.
- **Last updated:** 2014-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465230, "Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01465230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*